Citywire for Financial Professionals
Stay connected:

View the article online at http://citywire.co.uk/money/article/a1105849

Shire bid interest boosts fund manager backers

Takeover interest from Japan's Takeda sends pharmaceutical group to top of the FTSE 100, boosting fund manager backers.

 
Shire bid interest boosts fund manager backers
 

Shares in Shire (SHP) have jumped to the top of the FTSE 100 after Japan's largest drugmaker Takeda Pharmaceutical (4502.T) said it was considering a bid for the company.

Shares in the pharmaceutical group jumped 17.3% to £35.98, providing a boost to backers of the stock, which is popular among value-focused fund managers.

Jamie Seaton is the highest conviction investor in the stock, having built up a 9.9% position in his £321 million GVQ UK Focus . That's just below the 10% limit imposed by Financial Conduct Authority regulations, meaning today's jump is likely to force him to sell some of the stake.

The stock is meanwhile a top 5 position for Paul Major, manager of the BB Healthcare (BBH ) investment trust, accounting for 5% of the portfolio.

Shire has attracted backing from a number of value-focused investors, as its shares have drifted lower this year amid greater competition from generic drugs.

Alex Wright holds 3% of his Fidelity Special Values (FSV ) investment trust in the shares, while his colleague James Griffin has a 3.4% stake in his £561 million Fidelity Moneybuilder Growth fund.

Thomas Wilson is also a backer, with 3.9% of his £61 million F&C UK Alpha fund in the stock, while colleague David Moss has a 3.9% holding in the £61 million F&C UK Equity Income fund.

Other fund manager investors include Scott McKenzie, with 4.6% of his £14 million Saracen UK Alpha fund held in the stock; Henry Flockhart, with a 3.9% position in his £235 million Standard Life Investments UK Equity High Alpha fund; and Luke Chappell, with 3.3% of his £307 million BlackRock UK Equity fund.

Ketan Patel, co-manager of the EdenTree Amity UK fund, said a Takeda takeover would be 'a watershed moment for Japanese pharma'.

'There hasn’t been a cross border transaction in the sector, excluding joint ventures and small generic mergers and acquisitions,' he said.

'Takeda’s cash laden balance sheet appears a good fit for Shire’s struggling balance sheet, following recent large-scale mergers and acquisitions. The attraction for Takeda is the highly lucrative rare disease market in the US, which comes with exceedingly high margins and is largely exempt from the usual pricing pressure that affects the wider pharmaceutical sector.' 

Patel holds Shire in his EdenTree UK Equity Growth fund, which he runs with Phil Harris.

Takeda said its approach was 'at a preliminary and exploratory stage and no approach has been made to the board of Shire'.

Jefferies analyst Peter Welford, who rates Shire a 'buy', said he could 'see the potential strategic rationale for the deal' but flagged concerns over Takeda's relative size.

'We see the possible strategic fit given the Japanese pharma's focus  therapeutic areas of oncology, gastrointestinal and neuroscience, with Shire bolstering the latter two franchises,' he said.

'We note Takeda's current market cap is around $42 billion, which compares to Shire's $47 billion. We presume Takeda would need a significant equity raise to acquire Shire, suggesting a "merger" is perhaps better terminology, which may raise hurdles to the successful completion of any future deal.'

leave a comment

Please sign in here or register here to comment. It is free to register and only takes a minute or two.

News sponsored by:

The Citywire Guide to Investment Trusts


In this guide to investment trusts, produced in association with Aberdeen Asset Management, we spoke to many of the leading experts in the field to find out more.

Watch Now

More about this:

Look up the funds

  • GVQ UK Focus A
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • F&C UK Alpha
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • F&C UK Equity Income
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • TB Saracen UK Alpha Acc
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • Standard Life Inv UK Equity High Alpha
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • BlackRock UK Equity I Inc
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • Fidelity Moneybuilder Growth
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • EdenTree Amity UK A
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • EdenTree UK Equity Growth A
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Look up the shares

  • Shire PLC (SHP.L)
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Look up the investment trusts

  • Fidelity Special Values (Ordinary Share)
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • BB Healthcare Trust (Ordinary Share)
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Look up the fund managers

  • Henry Flockhart
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • Luke Chappell
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • Scott McKenzie
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • David Moss
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • Thomas Wilson
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • James Griffin
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • Alex Wright
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • Jamie Seaton
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • Susan Round
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • Ketan Patel
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them
  • Philip Harris
    Register or Sign in to receive email alerts for items in your favourites whenever we write about them

Archive

Today's articles

Tools from Citywire Money

From the Forums

+ Start a new discussion

Weekly email from The Lolly

Get simple, easy ways to make more from your money. Just enter your email address below

An error occured while subscribing your email. Please try again later.

Thank you for registering for your weekly newsletter from The Lolly.

Keep an eye out for us in your inbox, and please add noreply@emails.citywire.co.uk to your safe senders list so we don't get junked.

Read more...

Bookies slump as £2 stake limit on terminals looms

by Daniel Grote on Apr 24, 2018 at 15:19

Sorry, this link is not
quite ready yet